National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Adverse Drug Events (ADE) (4)
- (-) Adverse Events (6)
- Blood Clots (1)
- Blood Pressure (1)
- Cardiovascular Conditions (2)
- Children/Adolescents (1)
- Chronic Conditions (1)
- Comparative Effectiveness (1)
- (-) Diabetes (6)
- Heart Disease and Health (1)
- Labor and Delivery (1)
- Maternal Care (1)
- Medication (4)
- Medication: Safety (1)
- Mortality (1)
- Newborns/Infants (1)
- Outcomes (1)
- Patient Safety (2)
- Pregnancy (1)
- Risk (3)
- Women (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 6 of 6 Research Studies DisplayedHorton DB, Xie F, Chen L
Oral glucocorticoids and incident treatment of diabetes mellitus, hypertension, and venous thromboembolism in children.
The purpose of this study was to quantify rates of incident treatment for diabetes mellitus, hypertension, and venous thromboembolism (VTE) associated with oral glucocorticoid exposure in children aged 1-18 years. Participants were identified using US Medicaid claims data and included more than 930,000 children diagnosed with autoimmune diseases or a nonimmune comparator condition. Findings showed strong dose-dependent relationships between current glucocorticoid exposure and all outcomes, suggesting strong relative risks, but low absolute risks, of newly-treated VTE, diabetes, and especially hypertension in children taking high-dose oral glucocorticoids.
AHRQ-funded; HS021110.
Citation: Horton DB, Xie F, Chen L .
Oral glucocorticoids and incident treatment of diabetes mellitus, hypertension, and venous thromboembolism in children.
Am J Epidemiol 2021 Feb 1;190(3):403-12. doi: 10.1093/aje/kwaa197..
Keywords: Children/Adolescents, Diabetes, Chronic Conditions, Blood Clots, Medication: Safety, Medication, Adverse Drug Events (ADE), Adverse Events, Risk, Patient Safety, Blood Pressure
Hickson RP, Cole AL, Dusetzina SB
Implications of removing rosiglitazone's black box warning and restricted access program on the uptake of thiazolidinediones and dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes.
The purpose of this study was to describe trends over time in the initiation of rosiglitazone and pioglitazone-both in the thiazolidinedione (TZD) class-and medications from the dipeptidyl peptidase-4 (DPP-4) inhibitor class before and after the FDA removed a black box warning and restricted access program for rosiglitazone regarding an increased risk of myocardial infarction.
AHRQ-funded; HS000032.
Citation: Hickson RP, Cole AL, Dusetzina SB .
Implications of removing rosiglitazone's black box warning and restricted access program on the uptake of thiazolidinediones and dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes.
J Manag Care Spec Pharm 2019 Jan;25(1):72-79. doi: 10.18553/jmcp.2019.25.1.072..
Keywords: Adverse Drug Events (ADE), Adverse Events, Cardiovascular Conditions, Diabetes, Medication, Heart Disease and Health, Patient Safety
Brennan MB, Guihan M, Budiman-Mak E
Increasing SBP variability is associated with an increased risk of developing incident diabetic foot ulcers.
This study evaluated the relationship between increased systolic blood pressure (SBP) variability and risk of incident diabetic foot ulceration using a nested case-control design. The investigators found a graded relationship between SBP variability and risk of diabetic foot ulceration, providing a potential new and modifiable target to reduce this common complication.
AHRQ-funded; HS018542.
Citation: Brennan MB, Guihan M, Budiman-Mak E .
Increasing SBP variability is associated with an increased risk of developing incident diabetic foot ulcers.
J Hypertens 2018 Nov;36(11):2177-84. doi: 10.1097/hjh.0000000000001783..
Keywords: Adverse Events, Diabetes, Risk
Leonard CE, Han X, Brensinger CM
Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: a retrospective cohort study.
The purpose of this study was to examine and compare risks of serious hypoglycemia among antidiabetic monotherapy-treated adults receiving metformin, a sulfonylurea, a meglitinide, or a thiazolidinedione. The investigators found that sulfonylureas were associated with the highest rates of serious hypoglycemia. Among all study drugs, the highest rate was seen with glyburide. Pioglitazone was associated with a lower adjusted hazard for serious hypoglycemia vs metformin, while rosiglitazone and nateglinide had hazards similar to that of metformin.
AHRQ-funded; HS023898.
Citation: Leonard CE, Han X, Brensinger CM .
Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: a retrospective cohort study.
Pharmacoepidemiol Drug Saf 2018 Jan;27(1):9-18. doi: 10.1002/pds.4337..
Keywords: Risk, Adverse Drug Events (ADE), Adverse Events, Diabetes, Medication
Lee AK, Warren B, Lee CJ
The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes.
There is suggestive evidence linking hypoglycemia with cardiovascular disease, but few data have been collected in a community-based setting. This study found that hypoglycemia was not associated with stroke, heart failure, atrial fibrillation, or noncardiovascular and noncancer death. Results were robust within subgroups defined by age, sex, race, diabetes duration, and baseline cardiovascular risk.
AHRQ-funded; HS018542.
Citation: Lee AK, Warren B, Lee CJ .
The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes.
Diabetes Care 2018 Jan;41(1):104-11. doi: 10.2337/dc17-1669.
.
.
Keywords: Adverse Events, Cardiovascular Conditions, Diabetes, Mortality
Camelo Castillo W, Boggess K, Sturmer T
Association of adverse pregnancy outcomes with glyburide vs insulin in women with gestational diabetes.
The purpose of this study was to estimate the risks of adverse pregnancy outcomes among women receiving glyburide compared with insulin for the treatment of gestational diabetes mellitus (GDM) in a US population-based cohort. It found an association between glyburide (compared with insulin) and elevated risk of NICU admission, neonatal hypoglycemia, respiratory distress, birth injury, and large for gestational age in women with GDM.
AHRQ-funded; HS017950.
Citation: Camelo Castillo W, Boggess K, Sturmer T .
Association of adverse pregnancy outcomes with glyburide vs insulin in women with gestational diabetes.
JAMA Pediatr 2015 May;169(5):452-8. doi: 10.1001/jamapediatrics.2015.74..
Keywords: Adverse Drug Events (ADE), Adverse Events, Comparative Effectiveness, Diabetes, Labor and Delivery, Maternal Care, Medication, Newborns/Infants, Outcomes, Pregnancy, Women